CN1593392A - 一种辅酶q10冻干粉针剂及其制备方法 - Google Patents
一种辅酶q10冻干粉针剂及其制备方法 Download PDFInfo
- Publication number
- CN1593392A CN1593392A CN 200410015959 CN200410015959A CN1593392A CN 1593392 A CN1593392 A CN 1593392A CN 200410015959 CN200410015959 CN 200410015959 CN 200410015959 A CN200410015959 A CN 200410015959A CN 1593392 A CN1593392 A CN 1593392A
- Authority
- CN
- China
- Prior art keywords
- ubiquinone
- hours
- solution
- injectable powder
- lyophilized injectable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 title claims abstract description 78
- 235000017471 coenzyme Q10 Nutrition 0.000 title claims abstract description 77
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 title claims description 68
- 239000000843 powder Substances 0.000 title claims description 41
- 238000002360 preparation method Methods 0.000 title claims description 11
- 238000002347 injection Methods 0.000 title abstract description 16
- 239000007924 injection Substances 0.000 title abstract description 16
- 229940110767 coenzyme Q10 Drugs 0.000 title 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229920002675 Polyoxyl Polymers 0.000 claims abstract description 15
- 239000000203 mixture Substances 0.000 claims abstract description 9
- 239000004094 surface-active agent Substances 0.000 claims abstract description 7
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 claims description 67
- 229940035936 ubiquinone Drugs 0.000 claims description 67
- 239000000243 solution Substances 0.000 claims description 26
- 238000003756 stirring Methods 0.000 claims description 19
- 238000001035 drying Methods 0.000 claims description 17
- 238000004108 freeze drying Methods 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 15
- 229920000136 polysorbate Polymers 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 10
- 238000000859 sublimation Methods 0.000 claims description 8
- 230000008022 sublimation Effects 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 239000008215 water for injection Substances 0.000 claims description 7
- 239000012982 microporous membrane Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 150000003669 ubiquinones Chemical class 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 238000010257 thawing Methods 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 239000000155 melt Substances 0.000 claims 2
- 239000007788 liquid Substances 0.000 description 22
- 229940079593 drug Drugs 0.000 description 11
- 230000000694 effects Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 238000010579 first pass effect Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 235000021472 generally recognized as safe Nutrition 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004098 cellular respiration Effects 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000004531 microgranule Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 125000004151 quinonyl group Chemical group 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
4500LX光照 | 项目 | 样品 | 0天 | 5天 | 10天 |
外观及澄明度 | 粉针剂 | 橙黄色疏松块状,热融,再加水溶解后得橙黄色澄明液体 | 橙黄色疏松块状,热融,再加水溶解后得橙黄色澄明液体 | 橙黄色疏松块状,热融,再加水溶解后得橙黄色澄明液体 | |
小水针 | 橙黄色澄明液体 | 橙黄色澄明液体 | 橙黄色澄明液体 | ||
含量(以辅酶Q10计) | 粉针剂 | 100.0 | 98.73 | 96.85 | |
小水针 | 100.0 | 84.60 | 72.60 | ||
冲氧灌装,30℃ | 外观及澄明度 | 粉针剂 | 橙黄色疏松块状,热融,再加水溶解后得橙黄色澄明液体 | 橙黄色疏松块状,热融,再加水溶解后得橙黄色澄明液体 | 橙黄色疏松块状,热融,再加水溶解后得橙黄色澄明液体 |
小水针 | 橙黄色澄明液体 | 橙黄色澄明液体 | 橙黄色澄明液体 | ||
含量(以辅酶Q10计) | 粉针剂 | 100.0 | 98.56 | 96.34 | |
小水针 | 100.0 | 85.42 | 75.70 |
Claims (12)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100159599A CN100391447C (zh) | 2004-01-15 | 2004-01-15 | 一种辅酶q10冻干粉针剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100159599A CN100391447C (zh) | 2004-01-15 | 2004-01-15 | 一种辅酶q10冻干粉针剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1593392A true CN1593392A (zh) | 2005-03-16 |
CN100391447C CN100391447C (zh) | 2008-06-04 |
Family
ID=34663038
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100159599A Expired - Lifetime CN100391447C (zh) | 2004-01-15 | 2004-01-15 | 一种辅酶q10冻干粉针剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100391447C (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101066260B (zh) * | 2006-11-17 | 2012-11-07 | 姚瑶 | 一种辅酶q10乳剂及其冻干乳剂及制备方法 |
CN103191431A (zh) * | 2013-04-03 | 2013-07-10 | 郑云 | 一种不易结晶的辅酶q10氯化钠注射液及其制备方法 |
CN105380808A (zh) * | 2015-11-25 | 2016-03-09 | 陕西艾美雅生物科技有限公司 | 一种化妆品基质及其制备方法和使用方法 |
CN105380809A (zh) * | 2015-11-25 | 2016-03-09 | 陕西艾美雅生物科技有限公司 | 一种固态化妆品基质的制备方法及固态化妆品基质 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59163316A (ja) * | 1983-03-08 | 1984-09-14 | Eisai Co Ltd | けいれんの治療・予防剤 |
CN86100582A (zh) * | 1986-05-21 | 1987-12-02 | 泰州生物化学制药厂 | 一种使辅酶q10注射液保持澄明的方法 |
JP3889481B2 (ja) * | 1996-08-16 | 2007-03-07 | 株式会社カネカ | 医薬組成物 |
-
2004
- 2004-01-15 CN CNB2004100159599A patent/CN100391447C/zh not_active Expired - Lifetime
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101066260B (zh) * | 2006-11-17 | 2012-11-07 | 姚瑶 | 一种辅酶q10乳剂及其冻干乳剂及制备方法 |
CN103191431A (zh) * | 2013-04-03 | 2013-07-10 | 郑云 | 一种不易结晶的辅酶q10氯化钠注射液及其制备方法 |
CN103191431B (zh) * | 2013-04-03 | 2015-07-01 | 郑云 | 一种不易结晶的辅酶q10氯化钠注射液及其制备方法 |
CN105380808A (zh) * | 2015-11-25 | 2016-03-09 | 陕西艾美雅生物科技有限公司 | 一种化妆品基质及其制备方法和使用方法 |
CN105380809A (zh) * | 2015-11-25 | 2016-03-09 | 陕西艾美雅生物科技有限公司 | 一种固态化妆品基质的制备方法及固态化妆品基质 |
Also Published As
Publication number | Publication date |
---|---|
CN100391447C (zh) | 2008-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6306434B1 (en) | Pharmaceutical composition comprising cyclosporin solid-state microemulsion | |
US20120178675A1 (en) | Compositions And Methods For Modulating The Pharmacokinetics and Pharmacodynamics of Insulin | |
CN102068453B (zh) | 一种稳定的复合维生素组合物及其制备方法 | |
CN1196477C (zh) | 用于口服给药的药物组合物 | |
EA002776B1 (ru) | Фармацевтические композиции, содержащие циклодекстрины и таксоиды | |
EP3505161A1 (en) | Sublingual pharmaceutical composition of edaravone and (+)-2-borneol | |
WO2015192720A1 (zh) | 大剂量甘油在可耐受冻融脂肪乳剂中的应用 | |
Sasahara et al. | Dosage form design for improvement of bioavailability of levodopa II: bioavailability of marketed levodopa preparations in dogs and parkinsonian patients | |
CN102481288B (zh) | 含氨基酸稳定剂的替莫唑胺药物组合物及其制备方法 | |
JP3195360B2 (ja) | チアガビン塩酸塩を含有する医薬組成物およびその製法 | |
CN100391447C (zh) | 一种辅酶q10冻干粉针剂及其制备方法 | |
CN101022833A (zh) | 甘油二棕榈酸硬脂酸酯用于提高皮下或肌肉注射制剂中的蛋白质活性成分的生物利用度的用途 | |
CN104800172A (zh) | 注射用卡络磺钠粉针剂和制法 | |
JPS58189118A (ja) | 経鼻投与製剤 | |
CN111529494B (zh) | 一种谷维素胶束复合物固体分散体及其制备方法 | |
CN1194698C (zh) | 葛根素注射剂及其制备工艺 | |
CN108187060A (zh) | 药物载体、药物制剂及制备方法 | |
CN111465389B (zh) | 多西他赛共缀物的药物组合物及制备方法 | |
CN105796490A (zh) | 一种含氨基酸的尼莫地平注射液组合物及其制备方法 | |
CN111603439A (zh) | 一种长效依匹哌唑原位相变凝胶注射剂及其制备方法 | |
JP2007326796A (ja) | 金コロイドを含有する美白剤およびチロシナーゼ阻害剤 | |
CN1895230A (zh) | 赖诺普利滴丸及其制备方法 | |
CN103385851B (zh) | 用于抗癌的可注射用药物组合物 | |
Goel et al. | Pharmaceutical excipients | |
RU2367472C1 (ru) | Парентеральное лекарственное средство и способ его получения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: ZHEJIANG RUIDA PHARMACEUTICAL CO., LTD. HANGZHOU S Owner name: HAINAN POLY PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: FAN MINHUA Effective date: 20100707 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 310004 HOUSE 5, BUILDING 9, NO.167, HUANCHENG NORTH ROAD, HANGZHOU CITY, ZHEJIANG PROVINCE TO: 571127 GUILINYANG ECONOMIC AND TECHNOLOGICAL DEVELOPMENT ZONE, MEILAN DISTRICT, HAIKOU CITY, HAINAN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20100707 Address after: 571127 Guilin economic and Technological Development Zone, Meilan District, Hainan, Haikou Co-patentee after: Zhejiang Ruida Pharmaceutical Co.,Ltd. Patentee after: Hainan Poly Pharm Co.,Ltd. Co-patentee after: HANGZHOU SHARPLY PHARM R&D INSTIT. Co.,Ltd. Address before: 5, building 9, building 167, building 310004, Ring North Road, Hangzhou, Zhejiang Patentee before: Fan Minhua |
|
CI01 | Publication of corrected invention patent application |
Correction item: Patentee Correct: Zhejiang Ridae Pharmaceutical Co., Ltd. False: Zhejiang Ruida Pharmaceutical Co., Ltd. Number: 33 Volume: 26 |
|
CI03 | Correction of invention patent |
Correction item: Patentee Correct: Zhejiang Ridae Pharmaceutical Co., Ltd. False: Zhejiang Ruida Pharmaceutical Co., Ltd. Number: 33 Page: The title page Volume: 26 |
|
C56 | Change in the name or address of the patentee |
Owner name: HAINAN PLOY PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: HAINAN PULIN PHARMACEUTICAL CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 571127 Guilin economic and Technological Development Zone, Meilan District, Hainan, Haikou Patentee after: HAINAN POLY PHARM. Co.,Ltd. Patentee after: ZHEJIANG POLY PHARMACEUTICAL Co.,Ltd. Patentee after: HANGZHOU SHARPLY PHARM R&D INSTIT. Co.,Ltd. Address before: 571127 Guilin economic and Technological Development Zone, Meilan District, Hainan, Haikou Patentee before: Hainan Poly Pharm Co.,Ltd. Patentee before: Zhejiang Ruida Pharm Co.,Ltd. Patentee before: HANGZHOU SHARPLY PHARM R&D INSTIT. Co.,Ltd. |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20080604 |